FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression

Goran B. Klintmalm*, Bruce Kaplan, Allan D. Kirk

*Corresponding author for this work

Research output: Contribution to journalEditorial

4 Scopus citations
Original languageEnglish
Pages (from-to)971-972
Number of pages2
JournalAmerican Journal of Transplantation
Volume19
Issue number4
DOIs
StatePublished - Apr 2019
Externally publishedYes

Keywords

  • editorial/personal viewpoint
  • ethics
  • ethics and public policy
  • immunosuppressant
  • immunosuppression/immune modulation
  • insurance
  • law/legislation
  • lung transplantation/pulmonology

Fingerprint

Dive into the research topics of 'FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression'. Together they form a unique fingerprint.

Cite this